Hemiretinal vein occlusion with macular hemorrhage and edema treated with intravitreal bevacizumab

A 39-year-old male with decreased visual acuity and extensive macular hemorrhage and edema secondary to a hemiretinal vein occlusion was treated with multiple intravitreal injections of bevacizumab 1.25 mg every four to six weeks for over one year. Treatment outcomes were assessed by visual acuity a...

Descripción completa

Detalles Bibliográficos
Autores principales: Yalamanchi, Shalini, Flynn, Harry W
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2011
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3206123/
https://www.ncbi.nlm.nih.gov/pubmed/22069354
http://dx.doi.org/10.2147/OPTH.S23698
_version_ 1782215397259345920
author Yalamanchi, Shalini
Flynn, Harry W
author_facet Yalamanchi, Shalini
Flynn, Harry W
author_sort Yalamanchi, Shalini
collection PubMed
description A 39-year-old male with decreased visual acuity and extensive macular hemorrhage and edema secondary to a hemiretinal vein occlusion was treated with multiple intravitreal injections of bevacizumab 1.25 mg every four to six weeks for over one year. Treatment outcomes were assessed by visual acuity and Cirrus spectral domain optical coherence tomography. Treatment resulted in ongoing visual and anatomic improvement, with resolution at the last visit.
format Online
Article
Text
id pubmed-3206123
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-32061232011-11-08 Hemiretinal vein occlusion with macular hemorrhage and edema treated with intravitreal bevacizumab Yalamanchi, Shalini Flynn, Harry W Clin Ophthalmol Case Report A 39-year-old male with decreased visual acuity and extensive macular hemorrhage and edema secondary to a hemiretinal vein occlusion was treated with multiple intravitreal injections of bevacizumab 1.25 mg every four to six weeks for over one year. Treatment outcomes were assessed by visual acuity and Cirrus spectral domain optical coherence tomography. Treatment resulted in ongoing visual and anatomic improvement, with resolution at the last visit. Dove Medical Press 2011 2011-10-14 /pmc/articles/PMC3206123/ /pubmed/22069354 http://dx.doi.org/10.2147/OPTH.S23698 Text en © 2011 Yalamanchi and Flynn Jr., publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Case Report
Yalamanchi, Shalini
Flynn, Harry W
Hemiretinal vein occlusion with macular hemorrhage and edema treated with intravitreal bevacizumab
title Hemiretinal vein occlusion with macular hemorrhage and edema treated with intravitreal bevacizumab
title_full Hemiretinal vein occlusion with macular hemorrhage and edema treated with intravitreal bevacizumab
title_fullStr Hemiretinal vein occlusion with macular hemorrhage and edema treated with intravitreal bevacizumab
title_full_unstemmed Hemiretinal vein occlusion with macular hemorrhage and edema treated with intravitreal bevacizumab
title_short Hemiretinal vein occlusion with macular hemorrhage and edema treated with intravitreal bevacizumab
title_sort hemiretinal vein occlusion with macular hemorrhage and edema treated with intravitreal bevacizumab
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3206123/
https://www.ncbi.nlm.nih.gov/pubmed/22069354
http://dx.doi.org/10.2147/OPTH.S23698
work_keys_str_mv AT yalamanchishalini hemiretinalveinocclusionwithmacularhemorrhageandedematreatedwithintravitrealbevacizumab
AT flynnharryw hemiretinalveinocclusionwithmacularhemorrhageandedematreatedwithintravitrealbevacizumab

Ejemplares similares